Article Text

Download PDFPDF

456 Comparisons of clinical outcomes in women with advanced ovarian cancer treated with frontline intraperitoneal versus dose-dense platinum/paclitaxel chemotherapy without bevacizumab
  1. T Wan Hua,
  2. H Chi-Huang,
  3. C Hui-Hua,
  4. W Ming-Chow,
  5. L Ho-Hsiung and
  6. H Sheng-Mou
  1. Far Eastern Memorial Hospital, Taiwan


Background We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab.

Methods All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal or dose-dense platinum/paclitaxel chemotherapy and not receiving bevacizumab between March 2006 and June 2019 were reviewed.

Results A total of 50 women (intraperitoneal group, n=22; dose-dense group, n=28) were reviewed. Median progression-free survival (32.6 months versus 14.2 months; adjusted hazard ratio=0.38; 95% CI=0.16 to 0.90, p=0.03, figure 1a) and overall survival (not reached versus 30.7 months; adjusted hazard ratio=0.23, 95% CI=0.07 to 0.79, p=0.02, figure 1b) were significantly higher in the intraperitoneal group than in the dose-dense group. A multivariable Cox proportional-hazards model also indicated that the number of frontline chemotherapy cycles (adjusted hazard ratio=0.66, 95% CI 0.47 to 0.94, p=0.02, table 1) was a predictor of better overall survival. Nausea/vomiting and nephrotoxicity occurred more frequently in the intraperitoneal group (p=0.02 and <0.0001, respectively).

Abstract 456 Table 1

Cox proportional-hazards model to predict overall survival (n=50)

Abstract 456 Figure 1

Probabilities of (a) progression free survival and (b) overall survival between the intraperitoneal (IP) and dose-dense groups in all enrolled women (n = 50)

Conclusion Intraperitoneal chemotherapy seems to be superior in progression free survival and overall survival to dose-dense chemotherapy in the frontline treatment of women with advanced ovarian, fallopian tube or primary peritoneal cancer and not receiving bevacizumab.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.